Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer

[1]  V. Strand,et al.  059 A phase 3, randomised controlled trial comparing upadacitinib monotherapy to MTX monotherapy in MTX-naïve patients with active rheumatoid arthritis , 2019, Rheumatology.

[2]  Pengfei Guo,et al.  A meta-analysis of randomized controlled trials , 2019, Medicine.

[3]  M. Bertagnolli,et al.  Impact of consensus molecular subtyping (CMS) on overall survival (OS) and progression free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance). , 2017 .

[4]  Nan Song,et al.  Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial. , 2016, JAMA oncology.

[5]  R. Bernards,et al.  Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer. , 2016, Cancer research.

[6]  F. Markowetz,et al.  Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry , 2016, Clinical Cancer Research.

[7]  R. Strausberg,et al.  Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer , 2016, Science Translational Medicine.

[8]  P. Lønning,et al.  Intra-patient Inter-metastatic Genetic Heterogeneity in Colorectal Cancer as a Key Determinant of Survival after Curative Liver Resection , 2016, PLoS genetics.

[9]  V. Torri,et al.  Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[10]  H. Clevers,et al.  TGFβ signaling directs serrated adenomas to the mesenchymal colorectal cancer subtype , 2016, EMBO molecular medicine.

[11]  J. Luke,et al.  Correlation of WNT/β-catenin pathway activation with immune exclusion across most human cancers. , 2016 .

[12]  J. Desai,et al.  Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC). , 2016 .

[13]  D. Sargent,et al.  Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients. , 2016 .

[14]  P. Sharma,et al.  Immunologic profiling of consensus molecular subtype (CMS) stratified colorectal cancer (CRC) primary and liver metastectomy specimens: Implications for immune targeting of proficient mismatch repair CRC. , 2016 .

[15]  J. Meyerhardt,et al.  Impact of primary (1{o}) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance). , 2016 .

[16]  Jeffrey S. Morris,et al.  Association of primary (1{degrees}) site and molecular features with progression-free survival (PFS) and overall survival (OS) of metastatic colorectal cancer (mCRC) after anti-epidermal growth factor receptor ({alpha}EGFR) therapy. , 2016 .

[17]  J. Desai,et al.  Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results. , 2016 .

[18]  J. Desai,et al.  Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC). , 2016 .

[19]  Mark Lawler,et al.  Challenging the Cancer Molecular Stratification Dogma: Intratumoral Heterogeneity Undermines Consensus Molecular Subtypes and Potential Diagnostic Value in Colorectal Cancer , 2016, Clinical Cancer Research.

[20]  H. Welch,et al.  Colorectal Cancer on the Decline--Why Screening Can't Explain It All. , 2016, The New England journal of medicine.

[21]  M. Hattori,et al.  Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers , 2016, Nature Medicine.

[22]  S. Gabriel,et al.  Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma , 2016, Cell reports.

[23]  Etienne Becht,et al.  Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy , 2016, Clinical Cancer Research.

[24]  M. Belvin,et al.  MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade. , 2016, Immunity.

[25]  E. Haura,et al.  HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma , 2016, Clinical Cancer Research.

[26]  A. Ribas,et al.  Combination cancer immunotherapies tailored to the tumour microenvironment , 2016, Nature Reviews Clinical Oncology.

[27]  Michael R. Speicher,et al.  The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis , 2016, Science Translational Medicine.

[28]  Mari Mino-Kenudson,et al.  Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. , 2016, Cancer discovery.

[29]  C. Martins,et al.  Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities , 2016, Nature.

[30]  S. Durinck,et al.  Targeting PTPRK-RSPO3 colon tumours promotes differentiation and loss of stem-cell function , 2015, Nature.

[31]  R. Bosotti,et al.  Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer , 2015, Journal of the National Cancer Institute.

[32]  N Harmston,et al.  Wnt addiction of genetically defined cancers reversed by PORCN inhibition , 2015, Oncogene.

[33]  M. Kalos,et al.  Abstract A091: Targeting the TGFb pathway with galunisertib, a TGFbRI SMI, promotes antitumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition , 2016 .

[34]  L. Chin,et al.  Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression. , 2016, Cancer discovery.

[35]  T. Greten,et al.  A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer , 2016, Investigational New Drugs.

[36]  Eugenia G. Giannopoulou,et al.  Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH , 2015, Science.

[37]  R. Shoemaker,et al.  Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer , 2015, British Journal of Cancer.

[38]  P. LoRusso,et al.  Abstract C45: Phase I study of WNT974, a first-in-class Porcupine inhibitor, in advanced solid tumors , 2015 .

[39]  M. Ayers,et al.  A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer. , 2015, Journal of the National Cancer Institute.

[40]  M. Kalos,et al.  Targeting the TGFβ pathway with galunisertib, a TGFβRI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition , 2015, Journal of Immunotherapy for Cancer.

[41]  F. Loupakis,et al.  First-line chemotherapy for mCRC—a review and evidence-based algorithm , 2015, Nature Reviews Clinical Oncology.

[42]  R. Scharpf,et al.  The Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer , 2015, Nature.

[43]  M. Nowak,et al.  Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers , 2015, Nature Communications.

[44]  C. Atreya,et al.  Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  P. Gibbs,et al.  Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  Jeffrey S. Morris,et al.  The Consensus Molecular Subtypes of Colorectal Cancer , 2015, Nature Medicine.

[47]  J. Galon,et al.  Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy. , 2015, Cancer research.

[48]  R. Dienstmann,et al.  Heterogeneity of driver genes and therapeutic implications in colorectal cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  R. Strausberg,et al.  Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[50]  Ron Bose,et al.  HER2 activating mutations are targets for colorectal cancer treatment. , 2015, Cancer discovery.

[51]  E. Bik.  You Lose Some, You Win Some: Weight Loss Induces Microbiota and Metabolite Shifts , 2015, EBioMedicine.

[52]  Richard Ventura,et al.  Inhibition of de novo Palmitate Synthesis by Fatty Acid Synthase Induces Apoptosis in Tumor Cells by Remodeling Cell Membranes, Inhibiting Signaling Pathways, and Reprogramming Gene Expression , 2015, EBioMedicine.

[53]  W. Garrett,et al.  CCL2 Promotes Colorectal Carcinogenesis by Enhancing Polymorphonuclear Myeloid-Derived Suppressor Cell Population and Function , 2015, Cell reports.

[54]  D. Tu,et al.  Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. , 2015, European journal of cancer.

[55]  T. Aparicio,et al.  PD-1 blockade in tumors with mismatch-repair deficiency , 2015 .

[56]  Michael Peyton,et al.  Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. , 2015, Cancer discovery.

[57]  A. Santoro,et al.  O-008Phase II study of tivantinib (ARQ 197) in combination with Cetuximab in EGFR Inhibitor-resistant, MET-High, KRAS Wild-Type (KRASwt) Metastatic Colorectal Cancer (mCRC) , 2015 .

[58]  C. Atreya,et al.  LBA-07Updated Results of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC) , 2015 .

[59]  Beatriz Bellosillo,et al.  Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients , 2015, Nature Medicine.

[60]  Rodrigo Dienstmann,et al.  Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer. , 2015, Cancer discovery.

[61]  A. Jimeno,et al.  Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors , 2015, Clinical Cancer Research.

[62]  P. Stephens,et al.  Identification and characterization of RET fusions in advanced colorectal cancer , 2015, Oncotarget.

[63]  Hayley E. Francies,et al.  Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients , 2015, Cell.

[64]  Rodrigo Dienstmann,et al.  Optimal design of trials to demonstrate the utility of genomically‐guided therapy: Putting Precision Cancer Medicine to the test , 2015, Molecular oncology.

[65]  Marco Beccuti,et al.  The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets , 2015, Nature Communications.

[66]  U. Nielsen,et al.  Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic , 2015, Molecular Cancer Therapeutics.

[67]  Nikhil Wagle,et al.  Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. , 2015, Cancer discovery.

[68]  Pornpimol Charoentong,et al.  Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy , 2015, Genome Biology.

[69]  Sabine Tejpar,et al.  Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  Krishna R. Kalari,et al.  Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  Takanori Kanai,et al.  Modeling colorectal cancer using CRISPR-Cas9–mediated engineering of human intestinal organoids , 2015, Nature Medicine.

[72]  G. Inghirami,et al.  Stromal contribution to the colorectal cancer transcriptome , 2015, Nature Genetics.

[73]  Camille Stephan-Otto Attolini,et al.  Stromal gene expression defines poor-prognosis subtypes in colorectal cancer , 2015, Nature Genetics.

[74]  Derek J Richard,et al.  Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer , 2015, Molecular Cancer.

[75]  C. Curtis,et al.  A Big Bang model of human colorectal tumor growth , 2015, Nature Genetics.

[76]  K. Sakimura,et al.  Promotion of colorectal cancer invasion and metastasis through activation of NOTCH-DAB1-ABL-RHOGEF protein TRIO. , 2015, Cancer discovery.

[77]  L. Rubinstein,et al.  Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer , 2015, Investigational New Drugs.

[78]  Sabine Tejpar,et al.  IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies , 2015, Science Translational Medicine.

[79]  E. Akporiaye,et al.  STAT3 Signaling Is Required for Optimal Regression of Large Established Tumors in Mice Treated with Anti-OX40 and TGFβ Receptor Blockade , 2015, Cancer Immunology Research.

[80]  M. Salido,et al.  Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer , 2015, Clinical Cancer Research.

[81]  P. Angenendt,et al.  Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[82]  Tae Won Kim,et al.  Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs. cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC). , 2015 .

[83]  Stephanie Roessler,et al.  Integrative Genomic and Transcriptomic Characterization of Matched Primary and Metastatic Liver and Colorectal Carcinoma , 2015, International journal of biological sciences.

[84]  C. Bokemeyer,et al.  Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[85]  M. Wiese,et al.  Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[86]  R. Salazar,et al.  Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer. , 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[87]  K. Kinzler,et al.  The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints , 2015, Journal of Immunotherapy for Cancer.

[88]  K. Nishio,et al.  The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells , 2014, Oncotarget.

[89]  M. Yashiro.  Ulcerative colitis-associated colorectal cancer. , 2014, World journal of gastroenterology.

[90]  F T Bosman,et al.  Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[91]  Kristian Cibulskis,et al.  RNF43 is frequently mutated in colorectal and endometrial cancers , 2014, Nature Genetics.

[92]  Bruno Landi,et al.  Clinical Relevance of KRAS-Mutated Subclones Detected with Picodroplet Digital PCR in Advanced Colorectal Cancer Treated with Anti-EGFR Therapy , 2014, Clinical Cancer Research.

[93]  Nicolas Stransky,et al.  The landscape of kinase fusions in cancer , 2014, Nature Communications.

[94]  Vladimir Vacic,et al.  Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions , 2014, Genome Biology.

[95]  P. Newell,et al.  TGFβ Inhibition Prior to Hypofractionated Radiation Enhances Efficacy in Preclinical Models , 2014, Cancer Immunology Research.

[96]  L. Collette,et al.  Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[97]  J. Larkin,et al.  Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations , 2014, Clinical Cancer Research.

[98]  E. Van Cutsem,et al.  Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer , 2014, Clinical Cancer Research.

[99]  A. Bardelli,et al.  TGFα and Amphiregulin Paracrine Network Promotes Resistance to EGFR Blockade in Colorectal Cancer Cells , 2014, Clinical Cancer Research.

[100]  K. Aldape,et al.  Mutation and copy number discordance in primary versus metastatic colorectal cancer (mCRC). , 2014 .

[101]  A. Ghazalpour,et al.  Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[102]  M. Broggini,et al.  Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells , 2014, Oncotarget.

[103]  G. Coukos,et al.  Tumor Endothelium FasL Establishes a Selective Immune Barrier Promoting Tolerance in Tumors , 2014, Nature Medicine.

[104]  L. Trusolino,et al.  MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. , 2014, Cancer research.

[105]  A. Jemal,et al.  Colorectal cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[106]  Peter Ulz,et al.  Changes in Colorectal Carcinoma Genomes under Anti-EGFR Therapy Identified by Whole-Genome Plasma DNA Sequencing , 2014, PLoS genetics.

[107]  M. Choti,et al.  Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.

[108]  Jennifer B Dennison,et al.  Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer , 2014, Molecular Cancer Therapeutics.

[109]  Andreas Schlicker,et al.  Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition , 2013, International journal of cancer.

[110]  Justin Guinney,et al.  Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in Patients , 2013, Clinical Cancer Research.

[111]  M. Salto‐Tellez,et al.  AXL Is a Key Regulator of Inherent and Chemotherapy-Induced Invasion and Predicts a Poor Clinical Outcome in Early-Stage Colon Cancer , 2013, Clinical Cancer Research.

[112]  Michael Peyton,et al.  Systematic Identification of Molecular Subtype-Selective Vulnerabilities in Non-Small-Cell Lung Cancer , 2013, Cell.

[113]  Z. Trajanoski,et al.  Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. , 2013, Immunity.

[114]  D. Wheeler,et al.  Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab. , 2013, Neoplasia.

[115]  G. Botti,et al.  The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies , 2013, Cancer biology & therapy.

[116]  J. Tabernero,et al.  Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. , 2013, The New England journal of medicine.

[117]  Travis J Cohoon,et al.  Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. , 2013, Cancer discovery.

[118]  Sabine Tejpar,et al.  Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer , 2013, The Journal of pathology.

[119]  Andrea Bertotti,et al.  Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. , 2013, Cancer discovery.

[120]  E. White,et al.  Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids , 2013, Proceedings of the National Academy of Sciences.

[121]  J. Tabernero,et al.  Molecular dissection of microsatellite instable colorectal cancer. , 2013, Cancer discovery.

[122]  Mira Ayadi,et al.  Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value , 2013, PLoS medicine.

[123]  Florian Markowetz,et al.  Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions , 2013, Nature Medicine.

[124]  Lewis C Cantley,et al.  A colorectal cancer classification system that associates cellular phenotype and responses to therapy , 2013, Nature Medicine.

[125]  J. Ferlay,et al.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. , 2013, European journal of cancer.

[126]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[127]  Qi Liu,et al.  Expression of HGF and Met in Human Tissues of Colorectal Cancers: Biological and Clinical Implications for Synchronous Liver Metastasis , 2013, International journal of medical sciences.

[128]  John M. Asara,et al.  Glutamine supports pancreatic cancer growth through a Kras-regulated metabolic pathway , 2013, Nature.

[129]  N. Petrelli,et al.  Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[130]  H. Clevers,et al.  Intestinal Tumorigenesis Initiated by Dedifferentiation and Acquisition of Stem-Cell-like Properties , 2013, Cell.

[131]  A. Ballestrero,et al.  Low Percentage of KRAS Mutations Revealed by Locked Nucleic Acid Polymerase Chain Reaction: Implications for Treatment of Metastatic Colorectal Cancer , 2012, Molecular medicine.

[132]  D. Lam-Himlin,et al.  Serrated Lesions of the Colorectum: Review and Recommendations From an Expert Panel , 2013 .

[133]  Hsin-Chieh Yeh,et al.  Effect of the 2011 vs 2003 duty hour regulation-compliant models on sleep duration, trainee education, and continuity of patient care among internal medicine house staff: a randomized trial. , 2013, JAMA internal medicine.

[134]  G. Orphanides,et al.  Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines , 2012, BMC Medical Genomics.

[135]  J. Hecht,et al.  Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. , 2012, The Lancet. Oncology.

[136]  C. Datz,et al.  Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth , 2012, Nature.

[137]  F. Marincola,et al.  Cancer classification using the Immunoscore: a worldwide task force , 2012, Journal of Translational Medicine.

[138]  Charles J. Kahi,et al.  Serrated Lesions of the Colorectum: Review and Recommendations From an Expert Panel , 2012, The American Journal of Gastroenterology.

[139]  Melanie A. Huntley,et al.  Recurrent R-spondin fusions in colon cancer , 2012, Nature.

[140]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[141]  Victor Moreno,et al.  A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction , 2012, Gut.

[142]  T. Golub,et al.  Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion , 2012, Nature.

[143]  M. Alberts.  Cerebral hemorrhage, warfarin, and intravenous tPA: the real risk is not treating. , 2012, JAMA.

[144]  Enzo Medico,et al.  Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer , 2012, Nature.

[145]  V. Gebski,et al.  Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[146]  Gerald C. Chu,et al.  Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism , 2012, Cell.

[147]  D. Sargent,et al.  Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. , 2012, JAMA.

[148]  Mari Mino-Kenudson,et al.  EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. , 2012, Cancer discovery.

[149]  R. Bernards,et al.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.

[150]  F. Bosch,et al.  Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer , 2012, Nature Medicine.

[151]  C. Fontanillo,et al.  Unique genetic profile of sporadic colorectal cancer liver metastasis versus primary tumors as defined by high-density single-nucleotide polymorphism arrays , 2012, Modern Pathology.

[152]  Javier Sastre,et al.  Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior , 2012, BMC Cancer.

[153]  Davide Corà,et al.  A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. , 2011, Cancer discovery.

[154]  J. Galon,et al.  Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. , 2011, Cancer research.

[155]  E. Fearon.  Molecular genetics of colorectal cancer. , 2011, Annual review of pathology.

[156]  J. Brunet,et al.  Stem cell property epithelial‐to‐mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux™) efficacy in KRAS wild‐type tumor cells , 2011, Journal of cellular biochemistry.

[157]  Sabine Tejpar,et al.  Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. , 2010, The Lancet. Oncology.

[158]  M. Koch,et al.  Expression of an ASCL2 related stem cell signature and IGF2 in colorectal cancer liver metastases with 11p15.5 gain , 2010, Gut.

[159]  M. Pino,et al.  The chromosomal instability pathway in colon cancer. , 2010, Gastroenterology.

[160]  J. Pignon,et al.  Immunogenic death of colon cancer cells treated with oxaliplatin , 2010, Oncogene.

[161]  J. Reid,et al.  Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[162]  K. Kinzler,et al.  Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells , 2009, Science.

[163]  G. Parmigiani,et al.  The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.

[164]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[165]  R. Day,et al.  Low Overexpression of HER-2/Neu in Advanced Colorectal Cancer Limits the Usefulness of Trastuzumab (Herceptin®) and Irinotecan as Therapy. A Phase II Trial , 2004, Cancer investigation.

[166]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[167]  E. E. Gresch.  Genetic Alterations During Colorectal-Tumor Development , 1989 .